The combined inhibition of MDM2 and STAT3 presents a promising therapeutic strategy that warrants continued exploration in both ALL and other cancers characterized by p53 deficiency or STAT3 dysregulation. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.